DDInter1544 DDInter1379
Prucalopride is a dihydrobenzofurancarboxamide derivative from the benzofurane family that selectively stimulates 5-HT4 receptors and thus, it presents enterokinetic properties. The high selectivity of prucalopride allowed further development as it prevented the cardiac adverse reactions observed due to non-target effects of precedent therapies. Prucalopride was developed by Shire Development LLC and approved for use in Europe in 2009, in Canada on December 7, 2011 and by the FDA on December 17, 2018.
Palbociclib is a piperazine pyridopyrimidine that acts in the cell cycle machinery. It is a second generation cyclin-dependent kinase inhibitor selected from a group of pyridopyrimidine compounds due to its favorable physical and pharmaceutical properties. Palbociclib was developed by Pfizer Inc after the discovery that identified the cyclin-dependent kinases as key regulators of cell growth. It was originally FDA approved on March 2015 for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer and its indications were updated in April 2019 to include male patients based on findings from postmarketing reports and electronic health records demonstrating safety and clinical efficacy.
Palbociclib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Doravirine
Palbociclib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Escitalopram
Palbociclib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Hepatitis A Vaccine
Palbociclib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sufentanil
Palbociclib {u} may lead to a major life threatening interaction when taken with {v} Amprenavir
Palbociclib {u} may lead to a major life threatening interaction when taken with {v} Measles virus vaccine live attenuated
Palbociclib may cause a minor interaction that can limit clinical effects when taken with Doravirine
Palbociclib may cause a minor interaction that can limit clinical effects when taken with Escitalopram
Palbociclib may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine
Palbociclib may cause a moderate interaction that could exacerbate diseases when taken with Sufentanil
Palbociclib may lead to a major life threatening interaction when taken with Amprenavir
Palbociclib may lead to a major life threatening interaction when taken with Measles virus vaccine live attenuated